Zenas BioPharma (ZBIO)

• Market cap: $1.75B
• 1 day: -19.71%
• 5 days: -16.67%
• 1 month: -9.17%
• 3 months: 48.47%
• 6 months: 226.88%
• Year to date: 261.71%
• 1 year: 271.61%
• 5 years: 79.56%
• 10 years: 79.56%
• Sector: Healthcare
• Industry: Biotechnology

About: Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.

Employees: 130